Inferring disease course from differential exon usage in the wide titinopathy spectrumRandall Division of Cell and Molecular Biophysics and Cardiovascular Division, King’s College London BHF Centre of Research Excellence, London, UK ; Paediatric Neurology, Neuromuscular Service, Evelina’s Children Hospital, Guy’s and St Thomas’ Hospitals NHS Trust, London, UK.
Clinical Genetics Department, Guy’s and St Thomas NHS Foundation Trust, London, SE1 9RT, UK.
Universite Paris Est Creteil, INSERM, U955, IMRB, and Reference Center for Neuromuscular Disorders, APHP Henri Mondor University Hospital, Creteil, France.
Clinica MEDS, Santiago de Chile, Chile.
Institute of Human Genetics, University of Leipzig Hospitals and Clinics, Leipzig, 4275, Germany.
Child Neurology Unit. Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute (VHIR), Barcelona, Spain.
North West Thames Regional Service, Northwick Park and St. Mark's Hospitals, Harrow, London, UK.
Medical Genetics Laboratory, ASST Papa Giovanni XXIII, Bergamo, Italy.
Clinical Genetics Service, Pediatria 1-ASST Papa Giovanni XXIII, Bergamo, Italy.
Clinical Genetics Service, Pediatria 1-ASST Papa Giovanni XXIII, Bergamo, Italy.
Neuropaediatrics Department, Hospital Sant Joan De Déu, Institut De Recerca Sant Joan De Déu, Barcelona, 08950, Spain.
Neuropaediatrics Department, Hospital Sant Joan De Déu, Institut De Recerca Sant Joan De Déu, Barcelona, 08950, Spain.
Neuromuscular Unit, Department of Neurology, Hospital Sant Joan De Déu, Barcelona, Spain.
Voronezh NN Burdenko State Medical University, Voronezh, 394036, Russia ; Saratov State Medical University, Saratov, 410012, Russia.
Unité D'embryofoetopathologie, Service D'histologie-Embryologie-Cytogénétique, Hôpital Necker-Enfants Malades, Paris, France.
Department of Pediatric Genetics, Amrita Institute of Medical Sciences & Research Centre, Kochi, Kerala, India.
GeneDx, Gaithersburg, Maryland, USA.
GeneDx, Gaithersburg, Maryland, USA.
Marseille Medical Genetics, Aix Marseille Université, Faculté Des Sciences Médicales Et Paramédicales, Marseille, France.
Reference Center for Inherited Metabolic Diseases, Marseille University Hospital, France.
Helsinki University Central Hospital, Finland.
Helsinki University Central Hospital, Finland.
Transplantation Laboratory, Department of Pathology, University of Helsinki, Finland.
Unitat De Malalties Neuromusculars Pediàtriques, Hospital Universitari Vall D'Hebron, Barcelona, Spain.
Histology Department, Vall D'Hebron University Hospital, Barcelona, Spain.
Maternal Fetal Medicine Unit, Department of Obstetrics, Universitat Autònoma de Barcelona, Hospital Vall D'Hebron, Barcelona, Spain.
Folkhälsan Research Center, Helsinki, Uusimaa, Finland ; Harry Perkins Institute of Medical Research, Centre for Medical Research, University of Western Australia, Nedlands, Australia.
Folkhälsan Research Center, Helsinki, Uusimaa, Finland.
Folkhälsan Research Center, Helsinki, Uusimaa, Finland ; Department of Musculoskeletal Diseases, Tampere University Hospital, Tampere, Pirkanmaa, Finland.
Folkhälsan Research Center, Uusimaa, Helsinki, Finland.
Show others and affiliations
2024 (English)In: Annals of Clinical and Translational Neurology, E-ISSN 2328-9503, Vol. 11, no 10, p. 2745-2755Article in journal (Refereed) Published
Abstract [en]
Objective: Biallelic titin truncating variants (TTNtv) have been associated with a wide phenotypic spectrum, ranging from complex prenatal muscle diseases with dysmorphic features to adult-onset limb-girdle muscular dystrophy, with or without cardiac involvement. Given the size and complexity of TTN, reaching an unequivocal molecular diagnosis and precise disease prognosis remains challenging. Methods: In this case series, 12 unpublished cases and one already published case with biallelic TTNtv were collected from multiple international medical centers between November 2022 and September 2023. TTN mutations were detected through exome or genome sequencing. Information about familial and personal clinical history was collected in a standardized form. RNA-sequencing and analysis of TTN exon usage were performed on an internal sample cohort including postnatal skeletal muscles, fetal skeletal muscles, postnatal heart muscles, and fetal heart muscles. In addition, publicly available RNA-sequencing data was retrieved from ENCODE. Results: We generated new RNA-seq data on TTN exons and identified genotype–phenotype correlations with prognostic implications for each titinopathy patient (whether worsening or improving in prenatal and postnatal life) using percentage spliced in (PSI) data for the involved exons. Interestingly, thanks to exon usage, we were also able to rule out a titinopathy diagnosis in one prenatal case. Interpretation: This study demonstrates that exon usage provides valuable insights for a more exhaustive clinical interpretation of TTNtv; additionally, it may serve as a model for implementing personalized medicine in many other genetic diseases, since most genes undergo alternative splicing.
Place, publisher, year, edition, pages
John Wiley & Sons, 2024. Vol. 11, no 10, p. 2745-2755
National Category
Medical Genetics and Genomics Neurology Bioinformatics and Computational Biology
Research subject
Translational Medicine TRIM
Identifiers
URN: urn:nbn:se:his:diva-24485DOI: 10.1002/acn3.52189ISI: 001299553100001PubMedID: 39198997Scopus ID: 2-s2.0-85202521250OAI: oai:DiVA.org:his-24485DiVA, id: diva2:1895263
Funder
Academy of Finland, 339437Academy of Finland
Note
CC BY 4.0
First published: 28 August 2024
© 2024 The Author(s). Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Correspondence Address: M.F. Di Feo; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy; email: mariafrancescadifeo@gaslini.org
M.S. received support from the Academy of Finland (grant 339437), Association Française contre les Myopathies (grant 23281), Sydäntutkimussäätiö, and Samfundet Folkhälsan i Svenska, Finland. A.O. received supported by Magnus Ehrnrooth Foundation. B.U. received support from the European Joint Program on Rare Diseases (project IDOLS-G), Academy of Finland, Juselius Foundation, and Samfundet Folkhälsan i Svenska Finland. F.M. received support from the European Joint Program on Rare Diseases (project IDOLS-G) and Instituto de Salud Carlos III, Spain (project number AC19/00048). P.H. received support from the Jane and Aatos Erkko foundation.
2024-09-052024-09-052025-02-10Bibliographically approved